SOURCE: Medgenics

Medgenics

September 13, 2010 18:28 ET

Medgenics CEO to Present at Rodman and Renshaw Annual Global Investment Conference

MISGAV, ISRAEL and LONDON--(Marketwire - September 13, 2010) -  Medgenics (AIM: MEDU) (AIM: MEDG), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, today announced that Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, will give a presentation at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 14, 2010 at 3:15 pm Eastern time.

The conference will include a series of one-on-one meetings with institutional investors. Investors interested in scheduling a meeting with Dr. Pearlman and the management team can facilitate a request by contacting the leslie.wolf-creutzfeldt@grayling.com or alternatively contact their Rodman & Renshaw representative directly.

NOTES TO EDITORS:
Medgenics is a commercial-stage biopharmaceutical Company, developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009.

For more information please visit: www.medgenics.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made.

Contact Information

  • For further information, contact:
    Medgenics, Inc.
    Dr. Andrew L. Pearlman
    Phone: +972 4 902 8900

    Grayling, United States
    Leslie Wolf-Creutzfeldt
    Investor Relations
    Phone: +1 646 284-9472
    Email: leslie.wolf-creutzfeldt@grayling.com